<META HTTP-EQUIV="Content-Type" CONTENT="text/html; charset=iso-8859-1">
<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta name=Generator content="Microsoft Word 14 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
{font-family:Cambria;
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:24.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-family:"Cambria","serif";
color:#365F91;
font-weight:bold;}
span.EmailStyle19
{mso-style-type:personal;
font-family:"Calibri","sans-serif";
color:#1F497D;}
span.EmailStyle20
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>We have put the release up on the front page of our site in news and will include in our upcoming newsletter. Definitely would be helpful to have all the direct emails of support group members to be sure they all get the news and can be mobilized. Happy to do our part.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><div><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0067B1'>Rocco Rossi</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0067B1'><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#365F91'>President and Chief Executive Officer<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#365F91'>Managing Director, PCCN<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Arial","sans-serif";color:blue'><a href="mailto:rocco@prostatecancer.ca">rocco@prostatecancer.ca</a><o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0067B1'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse'><tr><td width=180 valign=top style='width:134.7pt;border:none;border-right:solid #00AEEF 1.0pt;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal><b><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0067B1'>Prostate Cancer Canada</span></b><b><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0067B1'><o:p></o:p></span></b></p><p class=MsoNormal><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0067B1'>2 Lombard Street, 3<sup>rd</sup> Floor Toronto, Ontario M5C 1M1 416-441-2131, Ext. 225 </span><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0067B1'><o:p></o:p></span></p></td><td width=257 valign=top style='width:192.75pt;padding:0cm 5.4pt 0cm 5.4pt'><p class=MsoNormal><b><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0067B1'>Cancer de la Prostate Canada</span></b><b><span style='font-size:11.0pt;font-family:"Arial","sans-serif";color:#0067B1;mso-fareast-language:EN-US'><o:p></o:p></span></b></p><p class=MsoNormal><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0067B1'>2, rue Lombard, 3<sup>e</sup> étage</span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p></o:p></span></p><p class=MsoNormal><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0067B1'>Toronto (Ontario) M5C 1M1<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0067B1'>416-441-2131 poste 225</span><span style='font-size:10.0pt;font-family:"Arial","sans-serif";color:#0067B1'><o:p></o:p></span></p></td></tr></table><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p></div><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> Glen Tolhurst [mailto:glen.tolhurst@sympatico.ca] <br><b>Sent:</b> November-22-13 9:29 AM<br><b>To:</b> hopespringpcsg@artslist.uwaterloo.ca<br><b>Cc:</b> 'Erin McKenzie'; 'PCCN- ON - Br - Jim Dorsey'; 'Mimeault, Isabelle-Anne [JOICA]'; Rocco Rossi; Anne Breakey Hart<br><b>Subject:</b> FW: FYI From finance.yahoo.com Topic:ZYTIGA(R)* Now Available for Men with Metastatic Prostate Cancer in British Columbia Prior to Chemotherapy<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><span style='color:#1F497D'>Hi all:</span><o:p></o:p></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Interesting announcement, below.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>It raises the question “who will step up to the plate?”.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Take care,<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><div><h1>ZYTIGA®* Now Available for Men with Metastatic Prostate Cancer in British Columbia Prior to Chemotherapy<o:p></o:p></h1><p id="yui_3_9_1_1_1385127541904_1233">TORONTO , Nov. 21, 2013 /CNW/ - Effective November 15, 2013 , British Columbia is the first province to include ZYTIGA<sup>®</sup> (abiraterone acetate) on its public formulary for men living with metastatic prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT).<sup>1</sup> Men living with advanced prostate cancer, their caregivers and health care professionals are encouraged to learn more about the specific eligibility criteria that are required to be met for reimbursement of ZYTIGA<sup>®</sup> by the B.C. Cancer Agency at the following <a href="http://www.bccancer.bc.ca/NR/rdonlyres/4478D9DB-662B-43C2-8839-6D3C374D3FAE/67240/STUpdateNov2013SupplementFinal.pdf">link</a>. <o:p></o:p></p><p id="yui_3_9_1_1_1385127541904_1234">"I support the B.C. Cancer Agency's decision to reimburse ZYTIGA<sup>®</sup> as I have seen the benefits of this treatment for men living with advanced prostate cancer," says Dr. Martin Gleave **, urologic surgeon and Executive Director, Vancouver Prostate Centre. "It's exciting to have an option now available for treatment earlier in the disease that can help delay progression and improve overall quality of life." <o:p></o:p></p><p id="yui_3_9_1_1_1385127541904_1182">In July 2011 , ZYTIGA<sup>® </sup>was approved by Health Canada for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who had received prior chemotherapy containing docetaxel after failure of ADT.<sup>2</sup> Health Canada approved a second indication for ZYTIGA<sup>®</sup> in May 2013 for the treatment of men with mCRPC who are asymptomatic or mildly symptomatic after failure of ADT.<sup>3</sup> <o:p></o:p></p><p>"The expansion of access to ZYTIGA<sup>®</sup> is welcome news for eligible men to help restrict this common and lethal disease," says Don Konantz , age 51 from Vancouver, BC . "On behalf of patients with metastatic prostate cancer and as the Chair of the Canadian Coalition to Cure Prostate Cancer, I congratulate British Columbia and the B.C. Cancer Agency for their leadership." <o:p></o:p></p><p><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><h1><span style='color:red'>Perhaps it is time for PCC to mobilize the troops across Canada to get the other provinces to follow suit. <o:p></o:p></span></h1><p><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p></div></div></body></html>